cathepsin

(redirected from Cathepsin S)
Also found in: Dictionary, Encyclopedia.
Related to Cathepsin S: Cathepsin L

cathepsin

 [kah-thep´sin]
an endopeptidase found in most cells, which takes part in cell autolysis and self-digestion of tissues.

ca·thep·sin

(kă-thep'sin),
One of a number of intracellular proteinases and peptidases (all endopeptidases) of animal tissues of varying specificities.

cathepsin

/ca·thep·sin/ (kah-thep´sin) one of a number of enzymes each of which catalyzes the hydrolytic cleavage of specific peptide bonds.

cathepsin

(kə-thĕp′sĭn)
n.
Any of various enzymes found in animal tissue that catalyze the hydrolysis of proteins into smaller proteins.

cathepsin

Any ENZYME that acts to split the interior PEPTIDE bonds of a protein, causing its decomposition.

cathepsin

or

kathepsin

the intracellular, proteolytic enzymes that bring about AUTOLYSIS.

cathepsin

a proteinase found in most cells, which takes part in cell autolysis and self-digestion of tissues.

cathepsin D
an acid hydrolase isolated from cartilage which plays a part in the endogenous degradation of proteoglycans in degenerative diseases of joints.
References in periodicals archive ?
The report provides a snapshot of the global therapeutic landscape for Cathepsin S (EC 3.
Measurement of Concentrations of Cathepsin S and Cystatin C.
Reportedly, compounds from Medivir's cathepsin S inhibitor project, including MIV-247, have shown good efficacy in experimental models of neuropathic pain, with no evidence of tolerance induction in longer-term studies.
We are excited by the potential that this cathepsin S inhibitor program has for the treatment of autoimmune diseases and how it will complement our pipeline," said Darlene Jody, MD, Head of Specialized Therapeutics Global Business Unit at Schering Group.
The project aims to develop a pharmaceutical for autoimmune and allergic disorders; based on the inhibition of the protease enzyme Cathepsin S.
Celera Genomics has designed and synthesized extremely potent and selective compounds which demonstrate picomolar inhibitory potency against the cathepsin S enzyme and which also show inhibitory activity in cell systems in the nanomolar range.
Cathepsin S is a member of a large family of cysteine proteases, enzymes that are responsible for the cleavage and breakdown of other natural proteins in normal biological processes.
Medivir and Peptimmune have a joint-venture program to develop Cathepsin S inhibitor drugs.
Orally-bioavailable and potent Cathepsin S inhibitor drug leads have already been developed.
The most recent milestone payment recognizes successful completion of a pivotal in vivo proof-of-concept study designed to confirm the utility of Cathepsin S inhibitors for further development activities in various potential therapeutic indications.
Approximately 10 months ago, Axys announced achievement of a milestone from Aventis (then Rhone-Poulenc Rorer) following the successful conclusion of in vivo efficacy proof-of-concept studies that confirmed the biological connection of Cathepsin S to the inflammatory process.
Axys currently has programs focusing on the development of inhibitors of several papain family cysteine proteases, including Cathepsin K, Cathepsin S and Cathepsin B, which Axys is pursuing for oncology applications.